IV Iron Treatments Linked To Anaphylaxis Risk: Study
Injectafer fared better than the competing IV iron supplements, Dexiron and Feraheme, which were three to eight times more likely to cause anaphylaxis.
March 31, 2022 By: Irvin Jackson
Injectafer fared better than the competing IV iron supplements, Dexiron and Feraheme, which were three to eight times more likely to cause anaphylaxis.
An initial status conference in the Depo-Provera MDL will be held on Friday, to discuss how the recently consolidated litigation will move forward during coordinated discovery and pretrial proceedings.
A federal judge is preparing a second round of AFFF lawsuits for early trials, and has asked the parties to make educational presentations on the risk of liver cancer and thyroid cancer from firefighting foam chemicals at a Science Day in June 2025.
Cartiva implant recall was finally issued in October 2024, following years of concerns about the high failure rate and problems with the device, per Pennsylvania man's lawsuit.
"*" indicates required fields